13D Filing: Broadfin Capital and Recro Pharma Inc. (REPH)

Page 1 of 9

Recro Pharma Inc. (NASDAQ:REPH): Kevin Kotler’s Broadfin Capital filed an amended 13D.

You can check out Broadfin Capital’s latest holdings and filings here.

Please follow Broadfin Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Broadfin Capital or update its stock holdings.

Follow Kevin Kotler's Broadfin Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Broadfin Capital 0 2,705,262 0 2,705,262 14.15%
Broadfin Healthcare Master Fund, Ltd 0 2,705,262 0 2,705,262 14.15%
Kevin Kotler 0 2,705,262 0 2,705,262 14.15%

Follow Kevin Kotler's Broadfin Capital

Page 1 of 9 – SEC Filing

UNITED
STATES

SECURITIES AND
EXCHANGE COMMISSION

WASHINGTON,
DC 20549

SCHEDULE 13D

THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)*

Recro Pharma, Inc.
(Name of Issuer)
Common Stock, $0.01 par value per share
(Title of Class of Securities)
75629F109
(CUSIP Number)

Broadfin Capital, LLC

300 Park Avenue, 25th Floor

New York, New York 10022

Telephone – (212) 808-2460

(Name, Address and Telephone Number of Person
Authorized to Receive

Notices and Communications)

November 30, 2017
(Date of Event Which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [ _ ].
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7 for other parties to whom copies are to be sent.
*   The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Societal Cdmo Inc. (NASDAQ:SCTL)

Page 1 of 9